Accessibility Menu
Immix Biopharma logo

Immix Biopharma(NASDAQ) IMMX

Market Cap$1.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+280%
5 YearN/A
1 Year+532%
1 Month+69%
Premium Feature
Moneyball Superscore
61/100
$14.02
+0.57%
+0.08Today
After hours$14.03+$0.01 (+0.07%)
Immix Biopharma last closing stock price
MetricPriceDate
Last closeUSD 14.032026-08-31
Immix Biopharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.09%USD 13.612026-08-24
1 month+68.63%USD 8.322026-07-31
3 month+67.72%USD 8.372026-06-02
Year to date+168.26%USD 5.232025-12-31
1 year+531.98%USD 2.222025-08-29
3 year+512.66%USD 2.292023-09-01
Since inception+279.84%USD 3.672021-12-16

Immix Biopharma Financials at a Glance

Market Cap

$1.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$39.92M

EPS (TTM)

-$0.88

P/E Ratio

-15.94

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$14.02

Volume

1,326,816.528

Open

$13.70

Previous Close

$14.03

Daily Range

$13.52 - $14.15

52-Week Range

$1.94 - $15.10

Estimated Earnings Date

Nov 6, 2026

IMMX News

No articles available.

IMMX: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immix Biopharma

Immix Biopharma, Inc. develops cell therapies for rare diseases. Its treatments target harmful protein build-up in vital organs. These therapies use the immune system to fight illness.

Fighting Disease at the Cellular Level

  • CAR-T NXC-201: Personalized cell therapy currently in clinical trials for light chain (AL) amyloidosis; designed to target plasma cells.
  • N-GENIUS Platform: Proprietary technology used to create next-generation chimeric antigen receptor (CAR-T) cell therapies for various diseases.
  • IMX-110: Tissue-specific therapy in early-stage trials for soft tissue sarcoma and other solid tumors.
  • Pipeline Candidates: Targeted agents like IMX-111 and IMX-120 designed to treat colorectal cancers and inflammatory bowel diseases.

Milestones in Clinical Development

  • Entered a license agreement on Dec. 8, 2022, for exclusive rights to anti-BCMA CAR-T technology.
  • Secured an $8.0 million grant from the California Institute for Regenerative Medicine on July 25, 2024.
  • Received FDA Breakthrough Therapy designation in January 2026 for its lead candidate NXC-201.
  • Raised $140.7 million through an underwritten public offering in May 2026 to fund clinical development.

Engineering More Effective Immune Responses

The company uses its N-GENIUS platform to create cell therapies with an optimized physical structure. Chimeric antigen receptor (CAR-T) cell therapy modifies immune cells to identify and destroy diseased cells.

The Numbers Behind the Research

  • Net loss was $21.6 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and short-term investments totaled $232.1 million as of June 30, 2026.
  • Research and development expenses were $11.3 million for the six-month period ended June 30, 2026.
  • Net proceeds from an underwritten public offering in May 2026 reached $140.7 million.

Bottom Line

Immix has shifted focus from early research to conducting late-stage clinical trials for rare immunological disorders. The company relies on capital offerings and grants to support its specialized cell therapy pipeline.

AI Generated • Aug 8, 2026

Industry

Biotechnology

Sector

Health Care

Employees

21

CEO

Ilya Rachman, MD, PhD

Website

www.immixbio.com

Headquarters

Los Angeles, CA 90064, US

IMMX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-38.44%

Return on Capital

-31.58%

Return on Assets

-16.69%

Earnings Yield

-6.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

71.54M

Volume

1.33M

Avg. Volume

1.82M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$41.82M

EBITDA

-$40.28M

Operating Cash Flow

-$38.50M

Capital Expenditure

-$591.11K

Free Cash Flow

-$39.09M

Cash & ST Invst.

$232.11M

Total Debt

$1.00M

Immix Biopharma Performance Analysis

Immix Biopharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Immix Biopharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Immix Biopharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.62-66.3%
20232023-12-31USD -0.8943.0%
20242024-12-31USD -0.76-14.1%
20252025-12-31USD -0.8916.9%
Immix Biopharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-9.1%
Q42025-12-31-16.7%
Q12026-03-3135.7%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$47.80M

N/A

Employees

21

N/A

Net Income

-$11.56M

-74.5%

EBITDA

-$11.54M

-76.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$232.11M

+1894.4%

Total Debt

$1.00M

-3.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$890.64K

-8.4%

Short Term Debt

$111.11K

+57.7%

Return on Assets

-16.69%

N/A

Return on Invested Capital

-18.20%

N/A

Free Cash Flow

-$11.76M

-116.2%

Operating Cash Flow

-$11.74M

-121.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZNTLZentalis Pharmaceuticals, Inc.
$3.76-1.05%
WHWKWhitehawk Therapeutics Inc
$4.54-1.73%
MGNXMacroGenics, Inc.
$3.99-3.39%
ORMPOramed Pharmaceuticals Inc.
$5.02-0.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About IMMX

What is the current price of Immix Biopharma?

Immix Biopharma is trading at $14.03 per share.

What is the 52-week range for Immix Biopharma?

Over the past 52 weeks, Immix Biopharma has traded between $1.94 and $15.10.

How much debt does Immix Biopharma have?

As of the most recent reporting period, Immix Biopharma reported total debt of $1.00M.

How much cash does Immix Biopharma have on hand?

Immix Biopharma reported $225.49M in cash and cash equivalents in its most recent financial results.

What is Immix Biopharma’s dividend yield?

Immix Biopharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services